Now showing items 1-2 of 2
Wharton's jelly-derived mesenchymal stem cell transplantation in a patient with hypoxic-ischemic encephalopathy: a pilot study
(Sage Publications Inc, 2018)
Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) have been introduced as a possible therapy in hypoxic-ischemic encephalopathy (HIE). We report a 16-year-old boy who was treated with WJ-MSCs in the course of HIE ...
Functional recovery after wharton's jelly-derived mesenchymal stem cell administration in a patient with traumatic brain injury: a pilot study
(TURKISH NEUROSURGICAL SOC, 2020)
AIM: To introduce a traumatic brain injury (TBI) patient who underwent stem cell transplantation (SCT) in order to minimize the remaining injury deficiencies. MATERIAL and METHODS: This study included a 29 years old ...